Successful Treatment of Persistent SARS-CoV-2 Infection in a B-Cell Depleted Patient with Activated Cytotoxic T and NK Cells: A Case Report
Jacek Jassem, Natalia Marek-Trzonkowska, Tomasz Smiatacz, Łukasz Arcimowicz, Ines Papak, Ewa Jassem, Jan Maciej Zaucha
Abstract
We report a lymphoma patient with profound B-cell deficiency after chemotherapy combined with anti-CD20 antibody successfully treated with remdesivir and convalescent plasma for prolonged SARS-CoV-2 infection. Viral clearance was likely attributed to the robust expansion and activation of TCR Vβ2 CD8+ cytotoxic T cells and CD16 + CD56- NK cells. This is the first presentation of TCR-specific T cell oligoclonal response in COVID-19. Our study suggests that B-cell depleted patients may effectively respond to anti-SARS-CoV-2 treatment when NK and antigen-specific Tc cell response is induced.
Topics & Concepts
Cytotoxic T cellImmunologyCD8CD20CD16MedicineVirologyT cellAntibodyAntigenBiologyImmune systemCD3BiochemistryIn vitroCOVID-19 Clinical Research StudiesImmune Cell Function and InteractionSARS-CoV-2 and COVID-19 Research